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Abstract
Introduction: The current markers of disease activity in Takayasu arteritis (TA) are insufficient for proper
assessment. We investigated circulating levels of unacylated and acylated ghrelin, leptin and adiponectin and their
relationships with disease activity in patients with TA.
Methods: This study included 31 patients with TA and 32 sex-, age- and body mass index-matched healthy
controls. Disease activity was assessed in TA patients using various tools, including Kerr’s criteria, disease extent
index-Takayasu, physician’s global assessment, radiological parameters, and laboratory markers. Plasma unacylated
and acylated ghrelin, and serum leptin and adiponectin levels were measured using an enzyme-linked
immunosorbent assay.
Results: Unacylated and acylated ghrelin levels were found to be significantly lower in TA patients than that in
healthy controls. Patients with active disease had lower unacylated ghrelin levels than those with inactive disease
and had lower acylated ghrelin levels than healthy controls. Ghrelin levels were negatively correlated with various
parameters of disease activity. The leptin/ghrelin ratio was significantly higher in TA patients than controls. It was
positively correlated with disease activity. There was a positive correlation between unacylated and acylated ghrelin
and a negative correlation between leptin and ghrelin. There was no statistical difference in adiponectin levels
between TA patients and controls. The radiological activity markers were positively correlated with other
parameters of disease activity.
Conclusions: This study suggests that plasma unacylated and acylated ghrelin levels may be useful in monitoring
disease activity and planning treatment strategies for patients with TA. The serum leptin level and leptin/ghrelin
ratio may also be used to help assess the disease activity.
Introduction
Takayasu arteritis (TA) is a granulomatous panarteritis
affecting large vessels, predominantly the aorta and its
main branches. The disease is characterised by an acute
phase with constitutional symptoms and followed by a
vascular phase presented with symptoms due to stenosis,
occlusion or aneurysms. However, these phases often
overlap during the disease course [1].
The diagnosis of TA is based on its suggestive clinical
features and imaging methods such as conventional
angiography, magnetic resonance angiography (MRA)
and ultrasonography (US). Conventional angiography is
the gold standard for diagnosis. It shows clear outlines
of the lumen of affected arteries, whereas MRA and US
can demonstrate thickening of the vascular wall of the
aorta and its major branches [2-5].
Monitoring the disease activity is of great importance
because intensive treatment is required in the active peri-
ods of TA. However, until now a reliable serological mar-
ker of disease activity has not been identified. Acute-phase
reactants, such as erythrocyte sedimentation rate (ESR)
and serum C-reactive protein (CRP) may demonstrate
active inflammation but their specificity and sensitivity are
quite low [6]. ESR is increased in nearly half of the patients
in clinical remission, while it is normal in 28% of the
patients with active disease [7]. The current criteria for the
assessment of disease activity in TA [7] are not sufficient
either.
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Ghrelin, a recently discovered hormone, is produced
primarily by cells in the stomach but is also expressed
in white adipose tissue [8]. It has been shown to affect a
number of different systems including growth hormone
release, feeding, gastric acid secretion, gastric motility,
and cell proliferation. Ghrelin and its receptor have
been identified in T cells. It is a potent anti-inflamma-
tory mediator in lymphocytes, monocytes and dendritic
cells. It inhibits oxidative stress, cellular apoptosis, cell
adhesion and proinflammatory cytokine expression and
promotes IL-10 expression and cell migration [9].
Ghrelin is expressed in two different forms, namely
acylated ghrelin and unacylated ghrelin. Initially, the
unacylated ghrelin was considered to be biologically
inactive but then a role of unacylated ghrelin in control-
ling the growth hormone (GH)-insulin-like growth fac-
tor 1 (IGF-I) axis has been demonstrated. Moreover,
both acylated and unacylated forms of ghrelin have been
shown to bind to common sites on cardiomyocytes and
endothelial cells mediating similar signals to inhibit cel-
lular apoptosis [10].
Adipokines, leptin and adiponectin are polypeptid hor-
mones produced mainly by adipose tissue. Leptin regu-
lates food intake and energy balance. It is now regarded
as a pivotal factor in the interplay between neuroendo-
crine function and the immune system [11,12]. Proin-
flammatory cytokines increase circulating leptin, which
in turn triggers cytokine release in monocytes/macro-
phages and stimulates T cell-mediated immunity during
acute inflammation [13,14]. However, leptin may also
limit the inflammatory response [15,16]. Adiponectin
has antidiabetic and anti-atherogenic effects. It also
appears to have anti-inflammatory properties because of
its antagonism against TNF-a [17].
To our knowledge, there is no study investigating
ghrelin and adipokines in TA, an inflammatory disease
that is frequently accompanied by aneroxia and weight
loss. In the current study, we aimed to investigate circu-
lating unacylated and acylated ghrelin, leptin and adipo-
nectin levels and to evaluate their relationships with
disease activity in patients with TA.
Materials and methods
Patients and controls
Patients with TA followed up in the Division of Rheu-
matology, Dokuz Eylul University Medical Faculty
(Izmir, Turkey) were called by telephone and invited to
the hospital to participate in this study. We obtained
detailed medical history and performed full physical
examination on each patient who agreed to take part in
this study. Thirty-two sex-, age- and body mass index
(BMI)-matched hospital workers were evaluated as
healthy controls.
The study was approved by the Dokuz Eylul Univer-
sity Ethics Committee for Non-invasive Clinical
Research (project ethics number: B.30.2.DEU.0.01.00.00/
15482). Written informed consent was obtained from all
participants before enrollment.
Assessment of disease activity
Disease activity was assessed using various tools includ-
ing Kerr’s criteria [7], disease extent index-Takayasu
(DEI.Tak) and physician’s global assessment (PGA) [18],
radiological parameters and acute-phase reactants.
Kerr’s criteria [7] are used to define active disease if two
of the following criteria are positive: 1) systemic features
with no other cause; 2) elevated ESR; 3) features of vascu-
lar ischemia or inflammation (claudication, diminished or
absent pulses, bruit, vascular pain, asymmetric blood pres-
sure; or 4) typical angiographic features (in this study,
MRA was also included to evaluate new vessel involve-
ment or disease progression).
DEI.Tak [18] is a new index that was developed for
follow up examinations of TA patients. DEI.Tak assesses
clinical findings (without imaging) at intervals of at least
6 months, but only includes new or worsening symp-
toms that have developed within the past 6 months. TA
patients with a DEI.Tak score ≥ 1.0 at the time of this
study were considered to have active disease. PGA is an
item included on DEI.Tak, in which the physician classi-
fies the disease status according to one of three cate-
gories: active disease, grumbling/persistent disease, or
inactive disease.
Digital subtraction angiography (DSA) had been per-
formed on all except one of the TA patients by the time
of diagnosis. According to the TA follow up protocol of
the Rheumatology and Radiology Board of our hospital,
the TA patients are followed using three-monthly B-
mode/ Doppler US and annual magnetic resonance ima-
ging (MRI) with MRA examinations. Bilateral carotid,
upper and lower extremity, renal and mesenteric arterial
and abdominal aorta Doppler US examinations were per-
formed to evaluate flow parameters and vessel wall thick-
ness in all TA patients. MRI examinations, including
examination of the aortic arch and supra-aortic arteries
with specific investigations of the vessel walls and black-
blood images were obtained before and after injection of
a paramagnetic contrast agent to evaluate vessel wall
enhancement. MRA examinations were performed to
evaluate the whole aorta and its main branches.
We categorized the patients as having active disease
based on the results of the radiological examinations if
any of the following findings were positive: 1) new vessel
involvement, as determined by any of the radiological
studies including DSA, MRA and Doppler US; 2)
increase in the carotid intima-media thickness (IMT)
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compared with a previous US examination; 3) the pre-
sence of vessel wall thickening and contrast enhance-
ment on MRI.
All US and Doppler US examinations were performed
by the same radiologist, as previously described [19],
using an HDI-5000scanner (Advanced Technology
Laboratories, Bothell, Washington, DC, USA) equipped
with 12 to 5 MHz and 7 to 5 MHz linear array imaging
probes. MR studies were performed by an Achieva 1.5T
MRI scanner (Philips Healthcare, Best, The Netherlands).
The serum C-reactive protein level (CRP, normal range
0.1 to 8.2 mg/L), erythrocyte sedimentation rate (ESR,
normal range 0 to 20 mm/hour), and total leukocyte and
neutrophil numbers were measured as laboratory para-
meters of disease activity in TA patients and compared
with those in the controls.
Measurement of unacylated and acylated ghrelin, leptin,
and adiponectin
Overnight fasting-state blood samples (K2 ethylenediami-
netetraacetic acid (EDTA)-treated and not) were
obtained from patients and controls. Plasma leptin, adi-
ponectin, unacylated ghrelin and acylated ghrelin levels
were measured by ELISA kits, commercially available
from Biovendor RDP (Brno, Czech Republic). The assays
were performed according to the manufacturer’s instruc-
tions. ELISA plates were coated with anti-human leptin,
adiponectin, unacylated ghrelin and acylated ghrelin anti-
bodies, respectively. Color was developed with 3,3’,5,5’-
tetramethylbenzidine (TMB) and absorbance was mea-
sured at 450 nm. Mean values were reported.
Statistics
The Kolmogorov-Smirnov test was used to determine if
each parameter followed a normal distribution. The
values are expressed as the mean ± SD, median, or per-
centage, as appropriate. For comparison of the groups,
Kruskal-Wallis analysis or chi-square tests were used.
When between-group significance was determined, data
were compared in pairs using the Mann-Whitney U-test.
Relationships were determined using the phi coefficient,
Spearman’s rho, or intraclass correlations. All statistical
analyses were performed using SPSS software (version
15.0; SPSS Inc., Chicago, IL, USA). Differences were con-
sidered significant at P < 0.05.
Results
Demographic and clinical features
In total, 31 patients (28 female and 3 male) who fulfilled
the American College of Rheumatology (ACR) criteria for
TA [20] were enrolled in this study. Their mean age was
44.2 years, and the median disease duration was 7 years
(range 1 to 30 years). Thirty-two healthy sex-, age- and
BMI-matched hospital workers (28 female and 4 male,
mean age 41.5 years) were evaluated as controls. The
demographic, clinical and laboratory features of patients
and controls are shown in Table 1.
According to the angiographic classification [21], eigh-
teen patients with TA (58.1%) had type 5 vessel involve-
ment, ten had type 1 (32.3%), two had type 4 (6.4%) and
one had type 2 (3.2%). Coronary artery involvement was
present in three of thirty-one TA patients. Nineteen TA
patients (68.7%) were using corticosteroid treatment during
the study period. Immunosuppressive treatments included
the following: methotrexate monotherapy in thirteen
patients (41.9%), methotrexate plus leflunomide in three
patients (9.7%), azathioprine monotherapy in ten patients
(32.3%), leflunomide monotherapy in three patients (9.7%),
and azathioprine plus leflunomide in one patient (3.2%).
One patient (3.2%) was not receiving treatment.
Five patients (16.1%) had undergone prior vascular
surgery and twenty (64.5%) had undergone percutaneous
angioplasty.
Disease activity in TA patients
According to Kerr’s criteria and the radiological defini-
tions, six (20%) and ten (33%) TA patients respectively
had active disease. Seventeen patients (53.1%) had a
DEI.Tak score ≥ 1.0 at the time of the study; these
patients were considered to have active disease. The
mean DEI-Tak score was 1.0 at the time of the study.
The increase in the mean DEI-Tak score value during
the last six months was calculated as 0.17. When the
patients were evaluated according to the criteria of
PGA, we found that six (19.4%) patients had active dis-
ease, seven (22.6%) had grumbling/persistent disease
and eighteen (58.1%) had inactive disease.
There was a significant positive correlation between
radiological activity markers and Kerr’s criteria, DEI-Tak
and PGA (r = 0.408, P = 0.023; r = 0.463, P = 0.009;
and r = 0.409, P = 0.031, respectively). Significant corre-
lation was also determined between Kerr’s criteria and
DEI.Tak and Kerr’s criteria and PGA (r = 0.566, P =
0.001 and r = 0.603, P = 0.001 respectively).
ESR and total leukocyte and neutrophil numbers were
higher in TA patients than in controls (Table 1). We
determined that the immunosuppressive treatment was
changed in eight TA patients and the glucocorticoid
dose was increased in three TA patients due to treat-
ment failure during the last month. Both the change in
immunosuppressive treatment and increase in glucocor-
ticoid dose correlated well with Kerr ’s criteria (r =
0.640, P < 0.001 and r = 0.667, P < 0.001, respectively),
PGA (r = 0.570, P = 0.002 and r = 0.400, P = 0.035,
respectively) and the radiological activity markers (r =
0.370, P = 0.042 and r = 0.471, P = 0.009, respectively).
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Unacylated and acylated ghrelin levels
Plasma unacylated and acylated ghrelin levels (319.3 ±
202.6 pg/mL and 120.5 ± 94.4 pg/mL, respectively) were
found to be significantly lower in TA patients than
healthy controls (623.2 ± 270.0 pg/mL and 180.9 ± 128.7
pg/mL, respectively) (P < 0.001 and P < 0.05, respectively)
(Table 2). Their levels were also lower in the patients
with active disease than those with inactive disease
according to PGA (P < 0.05 for unacylated ghrelin (Fig-
ure 1) although the difference in acylated ghrelin levels
did not reach statistical significance. Furthermore, the
level of acylated ghrelin was lower in TA patients with
active disease than in healthy controls according to both
PGA (P < 0.05) (Figure 1) and DEI-Tak (P < 0.05). There
was no difference in acylated ghrelin levels between inac-
tive patients and healthy controls (Figure 1).
The level of unacylated ghrelin was negatively corre-
lated with DEI.Tak and PGA (r = -0.428, p = 0.037 and r
= -0.501, p <0.001 respectively). There was also a nega-
tive correlation between unacylated ghrelin and CRP, and
the numbers of leukocyte and neutrophil (r = -0.269, p =
0.033; r = -0.373, p = 0.003 and r = -0.395, p = 0.001,
respectively) (Figure 2). The level of acylated ghrelin was
also negatively correlated with CRP levels, and with leu-
kocyte and neutrophil numbers (r = -0.379, P = 0.003, r =
-0.332, P = 0.01 and r = -0.322, P = 0.013, respectively)
(Figure 3).
The unacylated and acylated ghrelin levels were lower
in patients who underwent changes in immunosuppres-
sive medication than in patients who did not (P = 0.003
and P = 0.018, respectively). The unacylated and acylated
ghrelin levels were also found to be lower in patients
who underwent an increase in glucocorticoid dose than
in patients who did not undergo an increase in glucocor-
ticoid dose (P = 0.027 and P = 0.020, respectively). The
levels of acylated and unacylated ghrelin in TA patients
who had diabetes mellitus and hypertension were not sta-
tistically different from those who did not have these
comorbidities (P > 0.05). Positive correlation was found
between unacylated ghrelin and acylated ghrelin levels
(r = 0.679, P < 0.001) (Figure 4).
Leptin and adiponectin levels
Leptin level was higher in TA patients than in healthy
controls but the difference did not reach statistical signif-
icance (Table 2). It was positively correlated with neutro-
phil numbers (r = 0.262, P = 0.038). There was negative
correlation between leptin and unacylated and acylated
ghrelin levels (r = -0.325, P = 0.009 and r = -0.473, P <
0.001, respectively) (Figure 5). The level of leptin was
higher in patients who underwent an increase in gluco-
corticoid dose than those who did not (P < 0.05).
There was no statistical difference in adiponectin levels
between TA patients and healthy controls (Table 2). The
level of adiponectin was not different in the patients with
Table 1 Characteristics of the patients with Takayasu arteritis and matched healthy controls
Takayasu patients (n = 31) Healthy controls (n = 32) P
Age, years, mean ± SD 44.2 ± 11.3 41.5 ± 5.9 0.22
Sex, female/male, n 28/3 28/4 1.00
Body mass index, mean ± SD 25.2 ± 4.2 25.0 ± 3.3 0.87
Waist circumference, cm, mean ± SD 86.6 ± 13.0 83.4 ± 10.0 0.28
Hip circumference, cm, mean ± SD 102.9 ± 9.2 104 ± 7.5 0.59
Diabetes mellitus, n (%) 3 (9.7) 0
Hypertension, n (%) 12 (38.7) 0
Hyperlipidemia, n (%) 9 (29) 0
Coronary artery disease, n (%) 3 (9.6) 0
Ever smoked, n (%) 4 (12.9) 0
Menopausal, n (%) 11 (39.3) 0
White blood cells, n/uL, mean ± SD 8622 ± 3614 6681 ± 1237 0.002
Neutrophil, n/uL, mean ± SD 5754 ± 2747 3878 ± 1000 0.001
Hemoglobin, g/dL, mean ± SD 12.5 ± 1.7 12.9 ± 1.6 0.21
ESR, mm/hour, mean ± SD 28.3 ± 24.1 16.2 ± 8.5 0.017
C-reactive protein, mg/L, mean ± SD 11.7 ± 24.6 2.7 ± 3.0 0.11
ESR, erythrocyte sedimentation rate
Table 2 The levels of unacylated and acylated ghrelin,
leptin, and adiponectin in patients and controls
TA HC P
Unacylated ghrelin, pg/mL 319.3 ± 202.6 623.2 ± 270.0 < 0.001
Acylated ghrelin, pg/mL 120.5 ± 94.4 180.9 ± 128.7 < 0.05
Leptin, ng/mL 72 ± 62 52 ± 35 ➢ 0.05
Adiponectin, µg/mL 16 ± 9 13 ±5 ➢ 0.05
Results are presented as mean ± SD. TA, Takayasu arteritis; HC, healthy
controls.
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active disease compared with those with inactive disease
and the controls.
Leptin/ghrelin ratio
The ratio of leptin/ghrelin was significantly higher in
TA patients than in healthy controls (P = 0.001). It did
not differ between TA patients with active or inactive
disease. The ratio of leptin/ghrelin was correlated with
Kerr’s criteria, DEI.Tak, PGA, the radiological activity
parameters and neutrophil numbers (r = -0.367, P =
0.003; r = -0.370, P = 0.003; r = -0.332, P = 0.008; r =
-0.377, P = 0.002; r = 0.356, P = 0.004, respectively).
The effect of glucocorticoid treatment on ghrelin and
leptin levels
No significant differences were found in unacylated and
acylated ghrelin, and leptin levels between TA patients
using glucocorticoid treatment and those not using glu-
cocorticoid treatment (P = 0.162, P = 0.530 and P =
0.400, respectively).
The relationships of ghrelin and adipokines with BMI, and
waist and hip circumference
Unacylated and acylated ghrelin, and adiponectin levels
were negatively correlated with BMI (r = -0.302, P = 0.016;
r = -0.277, P = 0.033; and r = -0.306, P < 0.05, respec-
tively), waist circumference (r = -0.423, P = 0.001; r =
-0.445, P < 0.001 and r = -0.285, P = <0.05, respectively)
and waist/hip ratio (r = -0.416, P = 0.001; r = -0.356, P =
0.006; r = -0.404, P = 0.001, respectively). A negative cor-
relation between acylated ghrelin level and hip circumfer-
ence (r = -0.353, P = 0.006) was also determined. The
leptin level was positively correlated with BMI (r = 0.508,
P < 0.001), waist circumference (r = 0.435, P < 0.001) and
hip circumference (r = 0.546, P < 0.001).
The carotid artery ultrasound results
The mean right and left carotid artery IMT measure-
ments were 1.10 ± 0.61 mm and 0.92 ± 0.44 mm,
respectively. Among 31 patients with TA, 14 had diffuse
and homogeneous IMT >1 mm by B-mode US, which
Figure 1 Plasma ghrelin levels in patients with Takayasu’s arteritis (TA) and matched healthy controls. Patients with active disease had
lower unacylated ghrelin levels than those with inactive disease (A) and had lower acylated ghrelin levels than healthy controls (B).
Figure 2 Negative correlations between plasma unacylated ghrelin levels and serum C-reactive protein (CRP) (A) and white blood cell
count (WBC) numbers (B) and neutrophil numbers (C).
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had been defined as suggestive for involvement with TA.
Among these 14 patients, 10 (71.4%) were already
known to have carotid artery involvement identified by
angiography or MRA. There was no relationship
between mean carotid IMT and leptin, or ghrelin. The
adiponectin level was positively correlated with the
mean carotid IMT measurements (r = 0.522, P = 0.004).
Four patients with TA (13.8%) had carotid athero-
sclerotic plaques. Among them, two had coronary artery
involvement. There was a significant relationship
between the occurrence of carotid atherosclerotic plaque
and coronary artery involvement (P = 0.004).
Discussion
Our study demonstrated decreased levels of circulating
unacylated and acylated ghrelin in patients with TA.
The ghrelin levels in patients with active disease were
lower than those with inactive disease. Although the dif-
ference did not reach statistical significance, leptin levels
in patients with active disease were increased. We also
found that the leptin/ghrelin ratio was significantly
higher in TA patients than in healthy controls. There
was negative correlation between ghrelin levels and dis-
ease activity whereas the leptin/ghrelin ratio was posi-
tively correlated with disease activity. Furthermore, a
reverse relationship was observed between leptin and
ghrelin. The findings of decreased ghrelin and increased
leptin in the patients who underwent treatment changes
in the last month also supported the relationships of
these hormones with active disease.
In the review of literature, we could find no study of
the relationship of ghrelin and leptin with TA, and there
was only one study investigating ghrelin levels in sys-
temic vasculitis. In contrast to our results, this study
showed that active anti-neutrophil cytoplasmic antibody
(ANCA)-associated vasculitis is characterized by
increased serum ghrelin and decreased serum leptin,
both of which return to normal with successful therapy
[22]. However, studies that have been performed in
other forms of systemic vasculitis (including Henoch-
Schönlein purpura and Behcet’s disease) have shown
increased levels of leptin in active disease periods
[23-25]. Several studies have also reported increased lep-
tin levels in systemic lupus erythematosus (SLE) [26-30]
and rheumatoid arthritis (RA) patients [31-35], and
some have demonstrated their correlation with disease
activity [28,29,31-33,35]. There are a few reports on
ghrelin that have revealed contradictory results in
inflammatory rheumatic diseases. Increases in circulat-
ing ghrelin levels have been reported in ankylosing
spondylitis (AS)[36] and RA. However, other studies
have found significantly decreased ghrelin levels in
patients with RA and in a rat adjuvant-induced arthritis
model [37,38]. Decreased ghrelin levels have also been
reported in patients with juvenile idiopathic arthritis.
Furthermore, this last study has shown a significant rela-
tionship between ghrelin and disease activity [39].
All these studies confirmed the relationship of leptin
and ghrelin with inflammation but it is unclear how the
extent and severity of inflammation, the stage of disease
progression, nutritional status and/or stress can impact
this relationship. The other disease mechanisms may
also directly or indirectly influence these hormones or
the expression of their receptors in tissues. Thus, the
discrepancies in the results of the studies may be
explained by these factors as well as methodological
differences.
Ghrelin has been shown to inhibit the leptin-induced
cytokine expression in a dose-dependent manner, while
leptin has upregulated ghrelin receptor-secretagogue
receptor (GHS-R) expression on human T lymphocytes
[9]. Leptin is known as a pure chemo-attractant and
appears to have proangiogenic activity [40,41] whereas
ghrelin inhibits angiogenesis [42,43]. These findings
Figure 3 Negative correlations between plasma acylated ghrelin levels and serum C-reactive protein (CRP) (A) and white blood cell
(WBC) numbers (B) and neutrophil numbers (C).
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suggest the existence of a reciprocal regulatory network
by which ghrelin and leptin control immune cell activa-
tion, inflammation and angiogenesis [9]. The present
study also suggests a negative interaction between leptin
and ghrelin.
In most of the studies, only total ghrelin levels were
investigated and no attempts were made to differentiate
between circulating acylated versus unacylated ghrelin
levels [10]. In this study, we report a significant positive
relation between the levels of these two forms of ghrelin
in patients with TA and our results suggest that both of
them are related to the inflammation.
Some studies have reported that low ghrelin levels are
associated with type 2 diabetes, insulin resistance, and
hypertension [44,45]. Therefore, we investigated the
impact of comorbidities, including diabetes mellitus and
hypertension, on the study results but we found no dif-
ference in acylated and unacylated ghrelin levels between
Figure 4 Positive correlation between plasma unacylated and acylated ghrelin levels.
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TA patients who have these comorbidities and those who
do not. Decreased ghrelin level under endogenously or
exogenously induced hypercortisolism has been also
reported previously [46], but we did not find any differ-
ence in unacylated and acylated ghrelin levels between
patients using glucocorticoid treatment and those not
using glucocorticoid treatment.
Although the level of adiponectin in patients with TA
was not different from healthy controls, it was positively
correlated with carotid IMT measurements, suggesting
that there may be a relationship between adiponectin
and disease activity. To our knowledge, there are no
published data on adiponectin in TA or other systemic
vasculitis.
Several studies have shown that BMI and waist/hip
ratio positively correlate with leptin levels and negatively
correlate with adiponectin and ghrelin levels in various
disease groups and in healthy controls [47-51]. Therefore,
we used a matching method to control for confounding
effects due to anthropometric values. Meanwhile, our
results were consistent with the previous studies that
have shown these relationships.
The main limitation of our study is a lack of compari-
son of study variables between the pre-treatment and
post-treatment periods in TA patients. However, there
are several difficulties in performing a prospective study
in TA, which is not a common disease [52,53]. There are
problems in determining disease activity in patients with
TA because a reliable marker is not yet available [54,55]
and many patients with TA have persistent disease asso-
ciated with chronic low-grade inflammation. ESR and
CRP are the most frequently used tools in the assessment
of disease activity but their sensitivity and specificity are
quite low [54,55]. Serum IL-6, and regulated and normal
T cell-expressed and secreted (RANTES) levels have
been shown to be increased in active disease periods and
correlated with the disease activity score in patients with
TA. However, a larger sample size and additional studies
are required to confirm these results. Other studies that
have investigated several markers of endothelial injury,
platelet activity, and thrombotic and fibrinolytic status
have failed to show a significant relationship between
these markers and disease activity [56,57]. In contrast,
plasma endothelin-1 levels have been demonstrated to be
positively correlated with ESR in patients with TA [58].
A recent study reported that plasma levels of pentraxin-3
(PTX3), an acute phase reactant, which is produced by
vascular and immune cells in response to proinflamma-
tory signals, has greater accuracy for distinguishing active
from inactive disease than either ESR or CRP [59], but it
needs to be studied in a larger group of patients with
unknown disease activity. The value of these tests in fol-
low up is still uncertain.
We previously demonstrated that there is a very good
agreement between Kerr’s criteria and DEI.Tak, and
using Kerr’s criteria instead of DEI.Tak increases the con-
sistency with PGA [60]. The latter finding has suggested
that the physician’s decision could be influenced by the
acute-phase reactants and imaging modalities. In the pre-
sent study, we showed that radiological markers of dis-
ease activity are consistent with Kerr’s criteria, DEI-Tak
and PGA. Therefore, we suggest that the radiological
markers may help to evaluate disease activity in patients
with TA.
Conclusions
This study demonstrated decreased levels of unacylated
and acylated ghrelin in patients with TA. Patients with
active disease had lower unacylated ghrelin levels than
those with inactive disease and had lower acylated
Figure 5 Negative correlations between serum leptin and plasma unacylated ghrelin (A) and acylated ghrelin levels (B).
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ghrelin levels than healthy controls. Ghrelin levels were
negatively correlated with various parameters of disease
activity. Furthermore, the leptin/ghrelin ratio was higher
in TA patients than in controls. It was positively corre-
lated with disease activity. There was a positive correla-
tion between unacylated and acylated ghrelin and a
negative correlation between leptin and ghrelin. No dif-
ference was determined in adiponectin levels between
TA patients and controls.
The results of the study suggest that plasma unacylated
and acylated ghrelin levels may be useful in monitoring
disease activity and planning treatment strategies for
patients with TA. The leptin/ghrelin ratio may also be
used to help assess disease activity. Further studies are
needed to validate the use of these laboratory tests in
daily clinical practice.
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